Skip to main content
SpringerLink
Log in

Multiples Myelom

  • Chapter
Kompendium Internistische Onkologie

  • 152 Accesses

Zusammenfassung

Das multiple Myelom (MM) gehört zu den malignen lymphoproliferativen Erkrankungen des B-Zell-Systems. Die früher gebräuchliche Bezeichnung „Plasmozytom“ sollte wegen des unterschiedlichen klinischen Erscheinungsbildes und der meist unterschiedlichen Therapie nur für das solitäre und das extramedulläre Plasmozytom (s. Abschn. 8.3.1) benutzt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adamietz IA, Schöber C, Schulte RWM et al (1991) Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 20:111–116

    Article  PubMed  CAS  Google Scholar 

  • Alexanian R, Haut A, Khan AU et al (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680–1685

    Article  PubMed  CAS  Google Scholar 

  • Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80:887–890

    PubMed  CAS  Google Scholar 

  • Alberts DS, Salmon SE (1975) Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep 59:345–350

    PubMed  CAS  Google Scholar 

  • Alsina M, Fonseca R, Wilson EF et al (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103:3271–3277

    Article  PubMed  CAS  Google Scholar 

  • Anonymous (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trails. Myeloma Trialists’ Collaborative Group. J Clin Oncol 16:3832–3842

    Google Scholar 

  • Attal M, Harousseau J-L, Stoppa A-M et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91–97

    Article  PubMed  CAS  Google Scholar 

  • Attal M, Harousseau JL, Facon T et al (2003) InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502

    Article  PubMed  CAS  Google Scholar 

  • Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356

    PubMed  CAS  Google Scholar 

  • Barlogie B (2001) High-dose therapy and innovative approaches to treatment ofmultiple myeloma. Semin Hematol 38(Suppl 3):21–27

    Article  PubMed  CAS  Google Scholar 

  • Bataille R, Boccadoro M, Klein B et al (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733–737

    PubMed  CAS  Google Scholar 

  • Bartl R (1986) Der leise Beginn des multiplen Myeloms. Wie diagnostizieren und wann therapieren? Internist 27:192–200

    PubMed  CAS  Google Scholar 

  • Bartl R (1988) Histologic classification and staging of multiple myeloma. Hematol Oncol 6:107–113

    Article  PubMed  CAS  Google Scholar 

  • Berenson JR, Crowley JJ, Grogan TM et al (2002) Maintenance therapy with alternateday prednisone improves survival in multiple myeloma patients. Blood 99:3163–3168

    Article  PubMed  CAS  Google Scholar 

  • Berenson JR, Hillner BE, Kyle RA et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 20:3719–3736

    Article  PubMed  Google Scholar 

  • Bladé J, Samson D, Reece D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102(5):1115

    Article  PubMed  Google Scholar 

  • Chapel HM, Lee M, Hargreaves R et al (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063

    Article  PubMed  CAS  Google Scholar 

  • Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

    Article  PubMed  CAS  Google Scholar 

  • Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854

    Article  PubMed  CAS  Google Scholar 

  • Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA (2004) Thalidomide in cancer medicine. Ann Oncol 15:1151–1160

    Article  PubMed  CAS  Google Scholar 

  • Einsele H, Schäfer HJ, Hebart H et al (2003) Follow-up of patients with progressive multiplemyeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121(3):411–418

    Article  PubMed  Google Scholar 

  • Facon T, Avet-Loiseau H, Guillerm G et al (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566–1571

    Article  PubMed  CAS  Google Scholar 

  • Fermand JP, Ravaud P, Chevret S et al (1998): High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of amulticenter sequential randomized clinical trial. Blood 92:3131–3136

    PubMed  CAS  Google Scholar 

  • Fritz E, Ludwig H, Kundi M (1984) Prognostic relevance of cellular morphology in multiple myeloma. Blood 63:1072–1079

    PubMed  CAS  Google Scholar 

  • Fritz E, Ludwig H. (2000) Interferon-alpha treatment in multiple myeloma: metaanalysis of 30 randomised trials among 3948 patients. Ann Oncol. 11:1427–1436

    Article  PubMed  CAS  Google Scholar 

  • Fonseca R, Blood E, Rue M et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569–4575

    Article  PubMed  CAS  Google Scholar 

  • Fonseca R, Debes-Marun CS, Picken EB et al (2003) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562–2567

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Svensson H, Cavo M et al (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparisonbetween transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haemotol 113:209–216

    Article  CAS  Google Scholar 

  • Greipp PR, San Miguel JF, Fonesca R et al (2005). An international staging system (ISS) for myeloma. J Clin Oneol (im Druck)

    Google Scholar 

  • Gutierrez NC, Hernandez JM, Garcia JL et al (2001) Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 15:840–845

    Article  PubMed  CAS  Google Scholar 

  • Harousseau JL, Attal M (2003) High-dose therapy in multiple myeloma. Hematol J 4:163–170

    Article  PubMed  CAS  Google Scholar 

  • Jagannath S, Richardson P.G, Barlogie B (2004) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma. EHA Congress, Geneva, 10–14, Abstract 369

    Google Scholar 

  • Konigsberg R, Zojer N, Ackermann J et al (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18:804–812

    PubMed  CAS  Google Scholar 

  • Korst DR (1968) Current management of multiple myeloma. Wis Med J 67(11):566–568

    PubMed  CAS  Google Scholar 

  • Kuehl MW, Bergsagel LP (2002) Multiple myeloma: Evolving genetic events and host interactions. Nature Reviews-Cancer 2:175–187

    Article  PubMed  CAS  Google Scholar 

  • Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 346:564–569

    Article  PubMed  Google Scholar 

  • Lenhard RE Jr, Oken MM, Barnes JM et al (1984) High-dose cyclophosphamide. An effective treatment for advanced refractory multiple meyloma. Cancer 53:1456–1460

    Article  PubMed  Google Scholar 

  • Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699

    PubMed  CAS  Google Scholar 

  • Mandelli F, Avvisati G, Amadori S et al (1990) Maintenance therapy with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430–1434

    PubMed  CAS  Google Scholar 

  • Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842

    Google Scholar 

  • Myeloma Trialists’ Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020–1034

    Article  Google Scholar 

  • Osserman EF (1968) Plasma cell dyscrasias. Am J Med 44:256–269

    Article  Google Scholar 

  • Österborg A, Björkholm M, Björeman M et al (1993) Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 81:1428–1434

    PubMed  Google Scholar 

  • Palumbo A, Bertola A, Musto P (2004) Oral melphalan, prednisone and thalidomide for previously untreatedmyeloma patients. 9th EHACongress, Geneva, 10–14, Abstract 301

    Google Scholar 

  • Peest D, Deicher H, Coldewey R et al (1990) Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM DEX) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of amulticenter trial. The GermanMyeloma Treatment Group. Onkologie 13:458–460

    Article  PubMed  CAS  Google Scholar 

  • Peest D, Deicher H, Coldewey R et al (1995) A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A:146–151

    Article  PubMed  CAS  Google Scholar 

  • Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  PubMed  CAS  Google Scholar 

  • Salmon SE, Cassady JR (1997) Plasma cell neoplasm. In: De Vita V, Hellman S, Rosenberg S (eds) (1997) Cancer — Principles and Practice of Oncology, 5th ed. Lippincott-Raven, pp 2344–2387

    Google Scholar 

  • Shaughnessy J, Jacobson J, Sawyer J et al (2003) Continuous absence of metaphasedefined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood 101:3849–3856

    Article  PubMed  CAS  Google Scholar 

  • Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571

    Article  PubMed  CAS  Google Scholar 

  • Weber D, Rankin K, Gavino M, et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16–19

    Article  PubMed  CAS  Google Scholar 

  • Zojer N, Konigsberg R, Ackermann J et al (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925–1930

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Ludwig, H., Schmoll, H.J. (2006). Multiples Myelom. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_191

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_191

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation